Month: September 2019

Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

Revenue for the fourth quarter ended June 30, 2019 grew 20% to $1.92 million versus $1.60 million in the prior year comparable period.

TRTC 2019 Consortium – Viewpoint is a Sponsor and CSO gives a Presentation

September 20, 2019 | Madison, WI.

Michael K. Schultz, PhD, Co-Founder and Chief Science Officer of Viewpoint, presented “212Pb & 203Pb Theranostics for Cancer” at the 2019 Targeted Radionuclide Therapy Consortium (TRTC) held at the University of Wisconsin-Madison. This three-day meeting focuses on advancing nuclear medicine science and education for the societal benefit of personalized healthcare, and personnel from fields of radiochemistry, radiology, radiation oncology, and medical physics are integrated at this event to fulfill this mission. Viewpoint Molecular Targeting is a proud Gold Industry Sponsor of the 2019 TRTC.

To see more: TRTC 2019

Viewpoint Awarded $2 Million to Conduct a Phase 1 Clinical Trial at Mayo Clinic

September 20, 2019 | Coralville, IA.

Viewpoint Molecular Targeting, Inc. was awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $2 million from the National Cancer Institute (NCI). This award will support preclinical development and a phase 1 clinical imaging trial of a Viewpoint product in metastatic melanoma patients. The phase 1 clinical imaging trial will take place at Mayo Clinic in Rochester, MN and is an insightful key step of product development in advance of companion therapeutic trials.

“This award is an excellent next step in advancing Viewpoint’s new therapy to the clinical stage. We could not be more excited about our progress and to expand our clinical trial sites.”–MICHAEL SCHULTZ, Viewpoint Co-Founder and Chief Science Officer

A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

The publication reported on a study of a series of 571 patients who were treated with Cesium-131 prostate brachytherapy at the Chicago (IL) Prostate Cancer Center by radiation oncologist Dr. Brian J. Moran.

Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019

To listen to the conference call, please dial (844) 602-0380. For callers outside the U.S., please dial (862) 298-0970.

Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting

During the meeting, attendees will have the opportunity to learn about the mounting body of clinical evidence illustrating the expanding use of Cesium-131, now known as Cesium BluTM, and its effectiveness in treating recurrent brain cancers including meningiomas and brain metastases.

Scroll to top